8.46 -0.24 (-2.82%)
MEDX
Stock Details
Last Trade:8.46 Change:-0.24 (-2.82%) Prev Close:8.70 Open: 8.51 Days Range:8.40 – 8.63 52 Week Range: 3.40 - 10.12 Volume:1737906 P/E: N/AEPS:-1.50
View AllRecent Alerts 07/04/09
Recent Alert on 06/30/09 at 8:15am
Medarex (MEDX) Will Receive Milestone Payment from Novartis (NVO) for FDA Approval of Ilaris
Medarex (MEDX) Will Receive Milestone Payment from Novartis (NVO) for FDA Approval of Ilaris
Medarex, Inc. (NASDAQ: MEDX) today announced it will receive a milestone payment of an undisclosed amount from Novartis (NYSE: NVO) Pharma AG, in connection with the marketing approval from the U.S. FDA, to market Ilaris(R) (canakinumab, previously... Read More
Recent Alert on 06/30/09 at 8:15am
Medarex (MEDX) Will Receive Milestone Payment from Novartis (NVO) for FDA Approval of Ilaris
Medarex (MEDX) Will Receive Milestone Payment from Novartis (NVO) for FDA Approval of Ilaris
Recent Alert on 06/22/09 at 1:58pm
Needham Comments On Medarex (MEDX) After Encouraging Mayo Clinic Cancer News
Needham Comments On Medarex (MEDX) After Encouraging Mayo Clinic Cancer News
Recent Alert on 06/22/09 at 1:13pm
Unusual 11 Mid-Day Movers 6/22: SUAI, ATAI, PMRY, ONTY Higher; LNET, DAN, REXX, MTL Lower
Unusual 11 Mid-Day Movers 6/22: SUAI, ATAI, PMRY, ONTY Higher; LNET, DAN, REXX, MTL Lower
Recent Alert on 06/22/09 at 10:32am
Medarex (MEDX) calls active as shares up on prostate cancer treatment report
Medarex (MEDX) calls active as shares up on prostate cancer treatment report
View AllRecent Press Releases
Press Release on 06/30/09 at 8:00am
Medarex to Receive Milestone Payment for the Approval of Ilaris for the Treatment of Cryopyrin-Associated Periodic Syndrome
Medarex to Receive Milestone Payment for the Approval of Ilaris for the Treatment of Cryopyrin-Associated Periodic Syndrome
View AllRecent SEC Filings
View AllRecent Blog Posts
Blog Posts on 06/23/09 at 10:23am
Medarex's Vaccine-Like Prostate Cancer Treatment Shows Great Promise
Medarex's Vaccine-Like Prostate Cancer Treatment Shows Great Promise

